2篇
您的检索式：作者名="Mark Forrest Gordon"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 普拉克索缓释剂和速释剂治疗中国帕金森病患者的疗效及安全性对比评估:一项随机、双盲、双模拟平行组研究显示文摘帕金森病是一种慢性神经系统退行性疾病,主要临床表现为运动症状和非运动症状。早期帕金森病患者常应用多巴胺受体激动剂单药治疗,以延迟左旋多巴诱发的运动并发症;晚期帕金森病患者多应用左旋多巴联合多巴胺受体激动剂治疗,可减少已发生的运动并发症。普拉克索速释剂和缓释剂是非麦角类多巴胺受体激动剂,对D2家族受体呈现高度选择性,对D3受体更具亲和力,显示其良好的疗效和不良反应小的优势。虽已有国际研究证实普拉克索缓释剂和速释剂的疗效,但是还没有两者对中国帕金森病患者的对比评估研究。我们对普拉克索缓释剂和速释剂联合左旋多巴治疗在中国帕金森病患者中的疗效进行非劣效性评估。 | 王瑛 孙圣刚 朱遂强 刘春风 刘艺鸣 狄晴 商慧芳 任艳 陆长虹 Mark Forrest Gordon Nolwenn Juhel 陈生弟 | 2015 | 中华神经科杂志2015，48，4： | 11 |
| 2 | The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study显示文摘Objective:To evaluate the non-inferiority of pramipexole extended-release(ER)versus immediate-release(IR)in Chinese patients with Parkinson’s disease(PD)in a double-blind,randomized,parallel-group study.Methods:Subjects were Chinese patients with idiopathic PD with diagnosis≥2 years prior to trial,age≥30 years old at diagnosis,and Modified Hoehn and Yahr score 2-4 during‘on’-time.Subjects received treatment with pramipexole ER(n=234)or IR(n=239).Non-inferiority was based on the primary endpoint,the change from baseline to end of maintenance(week 18)in the UPDRS(Parts II+III)total score.Results:For the primary endpoint,the adjusted mean changes(standard error)of UPDRS Parts II+III at week 18 were−13.81(0.655)and−13.05(0.643)for ER and IR formulations,respectively,using ANCOVA adjusted for treatment and centre(fixed effect)and baseline(covariate).The adjusted mean between group difference was 0.8 for the 2-sided 95%CI(−1.047,2.566).Since the lower limit of the 2-sided 95%CI(−1.047)for treatment difference was higher than the non-inferiority margin of−4,non-inferiority between pramipexole ER and IR was demonstrated.The incidence of adverse events(AEs)was 68.8%in the ER arm and 73.6%in the IR arm with few severe AEs(ER:2.1%;IR:3.8%).Conclusion:Based on the UPDRS II+III score,pramipexole ER was non-inferior to pramipexole IR.The safety profiles of pramipexole ER and IR were similar.These results were based on comparable mean daily doses and durations of treatment for both formulations. | Ying Wang Shenggang Sun Suiqiang Zhu Chunfeng Liu Yiming Liu Qing Di Huifang Shang Yan Ren Changhong Lu Mark Forrest Gordon Nolwenn Juhel Shengdi Chen for the Pramipexole ER Study Team | 2014 | Translational Neurodegeneration2014，3，1： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员